Carlsmed Raises $52.5M in Series C Funding

Funding Rounds

▤ Summary

The round was led by B Capital and U.S. Venture Partners. Led by CEO Mike Cordonnier, Carlsmed has developed the aprevo® personalized surgery platform, which is designed to advance the standard of care for spine surgery one patient at a time. The company intends to use the funds to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025. Commenting on the news, Mike Cordonnier said: “Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”

$ Funding

$
Amount $52.5M Total raised
□
Date March 18, 2024 Announcement date
◎
Investors CARLSMED Lead investors
▥
Company - Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies